Phreesia, Inc. (NYSE:PHR) CFO Sells $85,018.95 in Stock

Phreesia, Inc. (NYSE:PHR) CFO Balaji Gandhi sold 3,195 shares of the stock in a transaction on Monday, January 6th. The stock was sold at an average price of $26.61, for a total value of $85,018.95. Following the completion of the sale, the chief financial officer now directly owns 148,509 shares in the company, valued at approximately $3,951,824.49. This represents a 2.11 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Balaji Gandhi also recently made the following trade(s):

• On Tuesday, October 15th, Balaji Gandhi sold 864 shares of Phreesia stock. The stock was sold at an average price of $21.03, for a total transaction of $18,169.92.

Phreesia Stock Up 5.3 %

PHR stock opened at $28.42 on Friday. The company has a market cap of $1.65 billion, a price-to-earnings ratio of -19.33 and a beta of 0.94. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.77 and a current ratio of 1.74. The business’s 50-day moving average is $22.70 and its two-hundred day moving average is $22.57. Phreesia, Inc. has a fifty-two week low of $17.07 and a fifty-two week high of $29.16.

Phreesia (NYSE:PHR) last issued its quarterly earnings data on Monday, December 9th. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.04. The firm had revenue of $106.80 million for the quarter, compared to analysts’ expectations of $106.33 million. Phreesia had a negative net margin of 20.43% and a negative return on equity of 32.78%. The business’s quarterly revenue was up 16.6% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.58) EPS. As a group, analysts forecast that Phreesia, Inc. will post -1.16 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have issued reports on the stock. Royal Bank of Canada raised shares of Phreesia from a “sector perform” rating to an “outperform” rating and lifted their target price for the stock from $24.00 to $32.00 in a report on Wednesday. KeyCorp boosted their price objective on shares of Phreesia from $28.00 to $30.00 and gave the stock an “overweight” rating in a report on Wednesday. JMP Securities reiterated a “market outperform” rating and set a $30.00 target price on shares of Phreesia in a research note on Tuesday, December 10th. Robert W. Baird decreased their price target on Phreesia from $34.00 to $30.00 and set an “outperform” rating for the company in a research note on Wednesday, December 11th. Finally, Truist Financial increased their price objective on Phreesia from $31.00 to $34.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. Eleven analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $30.64.

Institutional Investors Weigh In On Phreesia

A number of hedge funds have recently modified their holdings of PHR. International Assets Investment Management LLC raised its holdings in Phreesia by 2,179.7% in the 3rd quarter. International Assets Investment Management LLC now owns 1,459 shares of the company’s stock worth $33,000 after purchasing an additional 1,395 shares during the period. Lombard Odier Asset Management USA Corp purchased a new stake in Phreesia in the second quarter worth about $202,000. Point72 DIFC Ltd bought a new position in shares of Phreesia in the second quarter worth about $209,000. XTX Topco Ltd purchased a new position in shares of Phreesia during the 3rd quarter valued at about $247,000. Finally, Hsbc Holdings PLC bought a new position in shares of Phreesia during the 2nd quarter valued at approximately $301,000. Institutional investors own 92.10% of the company’s stock.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.